上海宇道生物技术

Yudao Biotechnology is a biopharmaceutical company focused on the discovery of allosteric small molecule drugs using a proprietary technology platform. By integrating structural biology, computational chemistry, and artificial intelligence, the company identifies novel allosteric binding sites on high-value, traditionally undruggable protein targets. Their primary focus is on developing next-generation therapies for oncology, targeting key drivers of tumor growth and resistance. Yudao's pipeline features several innovative programs, including allosteric inhibitors of SHP2 and KRAS. The company is headquartered in Shanghai and has received significant backing from prominent venture capital firms like Matrix Partners China and Qiming Venture Partners.